Teva Releases Q1 2026 Aide Memoire
Rhea-AI Summary
Teva (NYSE: TEVA) posted its Q1 2026 Aide Memoire to the Investors page to help investors ahead of first-quarter results. The document compiles previously disclosed public information, management commentary and select independent data.
Teva expects to release Q1 2026 results on April 29, 2026 at 7:00 AM ET, with a conference call at 8:00 AM ET.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
TEVA fell 1.6% while peers were mixed: VTRS down 1.82%, UTHR down 0.26%, NBIX down 0.7%, but RDY and TAK up 1.43% and 0.72%, suggesting stock-specific trading rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-03-03 | Strategic funding deal | Positive | +1.9% | $400M Blackstone growth capital to advance duvakitug phase 3 program. |
| 2026-02-24 | Investor conferences | Neutral | -0.9% | CEO participation in multiple March healthcare investor conferences. |
| 2026-02-20 | NDA acceptance | Positive | -0.3% | FDA accepts NDA for TEV-'749 once-monthly schizophrenia injection. |
| 2026-02-17 | Clinical data update | Positive | +1.3% | Phase 2b duvakitug maintenance data show durable efficacy in UC and CD. |
| 2026-01-28 | Full-year results | Positive | +2.1% | 2025 results and 2026 guidance highlight growth and pipeline positioning. |
Positive pipeline and strategic news often saw modest positive reactions, while regulatory or conference updates occasionally traded lower despite constructive content.
Over recent months, Teva reported several notable developments. On 2026-01-28, it highlighted $17.3B in 2025 revenues and a third consecutive year of growth, with a $2.40B free cash flow and debt reduction, which preceded a 2.09% gain. Positive phase 2b duvakitug data on 2026-02-17 and a $400M Blackstone funding deal on 2026-03-03 also aligned with modest gains. By contrast, FDA NDA acceptance for TEV-'749 and investor-conference participation saw slight negative price moves.
Market Pulse Summary
This announcement directs investors to Teva’s Q1 2026 aide memoire ahead of results due on April 29, 2026, with the release set for 7:00 AM ET and a follow-up call at 8:00 AM ET. It serves mainly as a housekeeping update, referencing previously disclosed information. In context of recent growth-focused news and pipeline progress, investors may pay close attention to how Q1 results track prior guidance and to any updates on key programs and capital allocation.
Key Terms
aide memoire technical
AI-generated analysis. Not financial advice.
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website.
Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
FAQ
Where can I find Teva's Q1 2026 Aide Memoire (TEVA)?
When will Teva (TEVA) release Q1 2026 results and hold the conference call?
What does Teva's Q1 2026 Aide Memoire include for investors?
Will Teva (TEVA) provide new financial figures in the Q1 2026 Aide Memoire?
How can investors join Teva's Q1 2026 conference call on April 29, 2026?
